This High-Yield Pharma Stock Looks Like an Incredible Bargain

When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of economic conditions.One big pharma name stands out as an exceptional opportunity: Bristol Myers Squibb (NYSE: BMY). The stock has been pummeled in 2025, plunging 23% year to date (at the time of this writing) amid broader market turbulence. This dramatic underperformance has created a rare buying opportunity for investors willing to look past short-term headwinds.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool